Small-molecule activators or inhibitors of METTL3, as well as inhibitors of FTO, ALKBH5, and IGF2BP1, showed considerable anticancer effects in some in vitro and animal models of cancer, suggesting that RNA m6A modification has good application prospects in tumor therapy (Lan et al., 2021). This evidence concerns the gene FTO and neoplasm.